ACON Stock Price, Aclarion, Inc. Quote, Chart

Market Summary

USD0.32-0.01

Delayed

-3.03%

ACON Stock Price

View Fullscreen

ACON RSI Chart

ACON Valuation

Market Cap

2.6M

Price/Earnings (Trailing)

-0.43

Price/Sales (Trailing)

43.72

EV/EBITDA

-0.1

Price/Free Cashflow

-0.54

ACON Price/Sales (Trailing)

ACON Profitability

Operating Margin

-29.48%

EBT Margin

-10203.53%

Return on Equity

-244.55%

Return on Assets

-164.38%

Free Cashflow Yield

-185.61%

ACON Fundamentals

ACON Revenue

Revenue (TTM)

60.0K

Rev. Growth (Yr)

-60.29%

Rev. Growth (Qtr)

-26.69%

ACON Earnings

Earnings (TTM)

-6.1M

Earnings Growth (Yr)

-102.72%

Earnings Growth (Qtr)

-89.6%

Breaking Down ACON Revenue

Last 7 days

14.3%

Last 30 days

6.7%

Last 90 days

-81.5%

Trailing 12 Months

-53.6%

How does ACON drawdown profile look like?

ACON Financial Health

Current Ratio

2.08

ACON Investor Care

Shares Dilution (1Y)

1569.60%

Diluted EPS (TTM)

-9.34

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	60.0K	0	0	0
2023	76.9K	83.3K	84.1K	75.4K
2022	57.5K	42.5K	49.9K	60.4K
2021	0	0	0	60.3K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aclarion, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2023	thramann jeffrey john	sold	-1,000	1,000	-1.00	executive chairman
Feb 16, 2023	thramann jeffrey john	bought	1,000	1,000	1.00	executive chairman
Dec 29, 2022	lorbiecki john paul	bought	10,000	0.44634	22,404	chief financial officer
Dec 29, 2022	ness brent	bought	8,807	0.543297	16,211	chief executive officer
Dec 28, 2022	ness brent	bought	961	0.42	2,289	chief executive officer
Dec 02, 2022	sc capital 1 llc	sold	-	-	-1,091,890	-
Dec 02, 2022	neal david k	acquired	-	-	152,128	-
Apr 22, 2022	bond ryan	bought	56,000	2.8	20,000	chief strategy officer
Apr 21, 2022	wesemann william	bought	47,850	4.35	11,000	-
Apr 21, 2022	ness brent	bought	4,350	4.35	1,000	chief executive officer

Which funds bought or sold ACON recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	sold off	-100	-3,159	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	new	-	4.00	4.00	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	new	-	33.00	33.00	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	unchanged	-	-20,797	1,203	-%
May 15, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-2,657	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	new	-	1,773	1,773	-%
May 15, 2024	CAPTRUST FINANCIAL ADVISORS	added	1,500	549	2,744	-%
May 15, 2024	CAPTRUST FINANCIAL ADVISORS	added	231	-62,450	32,435	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-4,607	-	-%
May 15, 2024	Hudson Bay Capital Management LP	added	1,500	-2,080	4,800	-%

Are Funds Buying or Selling ACON?

Are funds buying ACON calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ACON

No. of Funds

Unveiling Aclarion, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 29, 2024	white lion capital llc	0.0%	0	SC 13G/A
Mar 06, 2024	intracoastal capital, llc	4.99%	375,554	SC 13G
Jan 12, 2024	white lion capital llc	9.52%	80,000	SC 13G
Dec 29, 2023	white lion capital llc	0.0%	0	SC 13G/A
Oct 30, 2023	white lion capital llc	5.9%	487,500	SC 13G
Feb 03, 2023	nuvasive inc	14.4%	1,126,495	SC 13G

Recent SEC filings of Aclarion, Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
Apr 29, 2024	8-K	Current Report
Apr 12, 2024	8-K	Current Report
Mar 29, 2024	SC 13G/A	Major Ownership Report
Mar 28, 2024	10-K	Annual Report
Mar 06, 2024	SC 13G	Major Ownership Report
Feb 27, 2024	8-K	Current Report
Feb 27, 2024	424B4	Prospectus Filed
Feb 26, 2024	EFFECT	EFFECT
Feb 23, 2024	S-1/A	Initial Public Offering

Aclarion, Inc. News

Latest updates

Aclarion, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	-26.7%	10,114	13,797	19,065	17,072	25,470	22,520	18,222	10,676	9,026	11,977	10,865	25,620	11,830
Cost Of Revenue	0.3%	19,476	19,416	19,558	19,301	17,453	17,289	17,028	14,249	16,732	16,221	16,086	20,304	16,565
Gross Profit	-66.6%	-9,362	-5,619	-493	-2,229	8,017	5,231	1,194	-3,573	-7,706	-4,243	-5,221	5,316	-4,735
Operating Expenses	13.0%	1,265,945	1,120,723	1,161,682	1,403,971	1,189,281	947,691	1,634,454	2,209,175	765,394	1,064,374	792,034	631,940	455,807
S&GA Expenses	1.1%	181,056	179,035	192,896	207,790	177,284	144,548	159,388	124,759	69,308	121,608	78,377	64,961	65,868
R&D Expenses	8.3%	239,042	220,679	198,252	250,006	204,399	218,997	290,966	353,226	204,803	182,101	275,284	162,714	167,751
EBITDA Margin	-52.3%	-83.63	-54.91	-79.54	-82.40	-72.50	-89.63	-	-	-	-	-	-	-
Interest Expenses	-14.6%	335,824	393,438	166,332	47,139	1,380	2,070	2,070	1,340,666	162,740	167,243	167,626	82,829	57,214
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-89.6%	-2,399,102	-1,265,347	-998,010	-1,464,557	-1,183,460	-	-1,633,033	-3,554,862	-	-	-	-	-
EBT Margin	-56.7%	-102	-65.13	-84.02	-84.87	-91.93	-116	-	-	-	-	-	-	-
Net Income	-89.6%	-2,399,102	-1,265,347	-998,010	-1,464,557	-1,183,460	-944,610	-1,633,033	-3,554,862	-936,088	-1,014,169	-2,952,418	-465,844	-517,860
Net Income Margin	-56.7%	-102	-65.13	-54.57	-62.75	-95.15	-116	-143	-198	-93.39	-82.11	-	-	-
Free Cashflow	-205.1%	-2,238,557	-733,782	-952,512	-947,540	-1,013,113	-1,135,053	-1,098,108	-2,406,524	-309,427	-832,259	-829,021	-492,201	-246,468

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet										(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	51.5%	3,727	2,460	1,543	2,004	1,861	2,915	4,101	5,621	1,808	1,889
Current Assets	96.9%	2,538	1,289	365	798	676	1,701	2,880	4,389	565	732
Cash Equivalents	109.8%	2,143	1,021	171	615	458	1,473	2,666	3,803	60.00	453
Net PPE	-16.6%	1.00	2.00	2.00	2.00	3.00	3.00	4.00	7.00	11.00	13.00
Liabilities	-61.7%	1,222	3,188	-	-	-	-	-	1,381	8,738	7,619
Current Liabilities	-61.7%	1,222	3,188	2,371	1,994	736	689	1,168	1,381	-	7,619
Shareholder's Equity	444.2%	2,505	-727	-	10.00	1,125	2,226	2,933	4,240	-	-12,831
Retained Earnings	-5.4%	-46,680	-44,281	-43,016	-42,018	-40,553	-39,370	-38,425	-36,792	-33,109	-31,886
Additional Paid-In Capital	12.9%	49,186	43,554	42,188	42,028	41,679	41,596	41,358	41,032	-	19,054
Shares Outstanding	766.6%	7,154	825	8,231	513	491	491	5,523	273	57.00	57.00
Float	-	-	-	-	4,673	-	-	-	5,020	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)													(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Cashflow From Operations	-205.1%	-2,238	-733	-952	-947	-1,013	-1,135	-1,098	-2,406	-309	-832	-829	-492	-246
Share Based Compensation	-13.8%	86.00	100	137	137	83.00	-51.82	702	702	23.00	84.00	84.00	-	5.00
Cashflow From Investing	-87.7%	-63.66	-33.92	-12.97	-60.91	-11.72	-48.25	-38.66	-38.30	-82.65	-17.02	-10.16	-51.20	-23.63
Cashflow From Financing	109.8%	3,414	1,627	522	1,165	-	-	-	6,187	-	-	50.00	2,571	319

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ACON Income Statement

2024-03-31

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue
Revenue	$ 10,114	$ 25,470
Cost of revenue	19,476	17,453
Gross profit (loss)	(9,362)	8,017
Operating expenses:
Sales and marketing	181,056	177,284
Research and development	239,042	204,399
General and administrative	845,847	807,599
Total operating expenses	1,265,945	1,189,281
Income (loss) from operations	(1,275,307)	(1,181,264)
Other income (expense):
Interest expense	(335,824)	(1,380)
Loss on exchange of debt	(1,066,732)	0
Loss on extinguishment of debt	(111,928)	0
Changes in fair value of warrant and derivative liabilities	297,684	0
Other, net	93,005	(816)
Total other income (expense)	(1,123,795)	(2,196)
Income (loss) before income taxes	(2,399,102)	(1,183,460)
Income tax provision	0	0
Net income (loss)	(2,399,102)	(1,183,460)
Net income (loss) allocable to common stockholders	$ (2,399,102)	$ (1,183,460)
Net income (loss) per share allocable to common stockholders, basic	$ (0.44)	$ (2.39)
Net income (loss) per share allocable to common stockholders, diluted	$ (0.44)	$ (2.39)
Weighted average shares of common stock outstanding, basic	5,442,625	496,159
Weighted average shares of common stock outstanding, diluted	5,442,625	496,159

ACON Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 2,132,635	$ 1,021,069
Restricted cash	10,000	10,000
Accounts receivable, net	17,213	13,270
Prepaids and other current assets	378,461	245,030
Total current assets	2,538,309	1,289,369
Non-current assets:
Property and equipment, net	1,486	1,782
Intangible assets, net	1,187,467	1,168,623
Total non-current assets	1,188,953	1,170,405
Total assets	3,727,262	2,459,774
Current liabilities:
Accounts payable	195,714	760,535
Accrued and other liabilities	288,129	857,722
Note payable, net of discount	670,150	1,125,724
Warrant liability	34,825	289,165
Derivative liability	32,994	121,326
Liability to issue equity	0	33,297
Total current liabilities	1,221,812	3,187,769
Total liabilities	1,221,812	3,187,769
Stockholders' equity
Common stock - $0.00001 par value, 200,000,000 authorized and 7,153,500 and 825,459 shares issued and outstanding (see Note 11)	72	8
Additional paid-in capital	49,186,006	43,553,523
Accumulated deficit	(46,680,628)	(44,281,526)
Total stockholders’ equity (deficit)	2,505,450	(727,995)
Total liabilities and stockholders’ equity	$ 3,727,262	$ 2,459,774

About Aclarion, Inc.

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. The company develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in Broomfield, Colorado.

CEO	Mr. Brent Ness
WEBSITE	aclarion.com
INDUSTRY	Healthcare Plans
EMPLOYEES	7

Aclarion, Inc. Frequently Asked Questions

What is the ticker symbol for Aclarion, Inc.? What does ACON stand for in stocks?

ACON is the stock ticker symbol of Aclarion, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aclarion, Inc. (ACON)?

As of Fri May 17 2024, market cap of Aclarion, Inc. is 2.63 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACON stock?

You can check ACON's fair value in chart for subscribers.

What is the fair value of ACON stock?

You can check ACON's fair value in chart for subscribers. The fair value of Aclarion, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aclarion, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACON so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aclarion, Inc. a good stock to buy?

The fair value guage provides a quick view whether ACON is over valued or under valued. Whether Aclarion, Inc. is cheap or expensive depends on the assumptions which impact Aclarion, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACON.

What is Aclarion, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ACON's PE ratio (Price to Earnings) is -0.43 and Price to Sales (PS) ratio is 43.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACON PE ratio will change depending on the future growth rate expectations of investors.